1. Revolution Medicines' KRAS Drug Posts Stunning Survival Data at AACR, NCI Director Addresses Funding Fears
The American Association for Cancer Research (AACR) annual meeting has been dominated by a single, stunning data release. Biotechnology firm Revolution Medicines presented results showing its experimental KRAS-targeting drug, daraxonrasib, more than doubled survival in second-line pancreatic cancer patients compared to...